BMY

EX-99.1

2 a2026q2ex991-filing.htm

PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JULY 30, 2026

Document

Exhibit 99.1

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook

Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress

•Second quarter revenues increased 6% (+5% Ex-FX) to $13.0 billion

◦Growth Portfolio revenues increased 15% (+14% Ex-FX) to $7.6 billion

•GAAP EPS was $1.62 and non-GAAP EPS was $2.04

•Raising 2026 revenue guidance to a range of ~$49.0 billion to $50.0 billion; Increasing non-GAAP EPS range to $6.75 to $7.00

(PRINCETON, N.J., July 30, 2026) – Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2026.

“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "We are building from a position of strength and progressing a differentiated pipeline designed to generate long-term value. As a result of our consistent execution and continued momentum, we are raising our 2026 full-year outlook."

Second Quarter Results

$ in millions, except per share amounts20262025Change Change Excl. FX**

Total Revenues$12,973 $12,269 6 %5 %

Earnings/(Loss) Per Share - GAAP*1.62 0.64 153 %N/A

Earnings/(Loss) Per Share - Non-GAAP*2.04 1.46 40 %N/A

Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Share 0.01 (0.57)N/AN/A

*GAAP and Non-GAAP earnings/(loss) per share include the net impact of Acquired IPRD charges and licensing income.

**See "Use of Non-GAAP Financial Information".

1

SECOND QUARTER RESULTS*

•Growth Portfolio revenues of $7.6 billion increased 15%, or 14% Ex-FX. Revenue growth was primarily driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag.

•Legacy Portfolio revenues of $5.4 billion decreased 4%, or 5% Ex-FX. Demand increased for Eliquis, which was more than offset by expected continued generic impacts across the remainder of the Legacy Portfolio.

•Total revenues of $13.0 billion increased 6%, or 5% Ex-FX.

◦U.S. revenues of $9.0 billion increased 6%.

◦International revenues of $4.0 billion increased 6%, or 5% Ex-FX.

*All comparisons are made versus the same period in 2025 unless otherwise stated.

SECOND QUARTER PRODUCT REVENUE HIGHLIGHTS(e)

($ amounts in millions)Quarter Ended June 30, 2026 % Change from Quarter Ended June 30, 2025

% Change from Quarter Ended June 30, 2025 Ex-FX**

U.S.

Int'l WW(d)

U.S.

Int'l

WW(d)

Int'l

WW(d)

Growth Portfolio

Opdivo$1,417 $1,068 $2,485 (6)%1 %(3)%(1)%(4)%

Opdivo Qvantig206 55 261 >200%>200%>200%>200%>200%

Orencia801 233 1,034 13 %(8)%7 %(8)%7 %

Yervoy481 288 769 7 %4 %6 %2 %5 %

Reblozyl593 142 735 31 %24 %29 %24 %29 %

Breyanzi354 131 484 39 %48 %41 %47 %41 %

Opdualag294 55 349 17 %72 %23 %65 %22 %

Camzyos310 105 416 45 %129 %60 %124 %59 %

Zeposia116 53 169 11 %17 %12 %14 %12 %

Sotyktu51 36 87 19 %30 %23 %27 %23 %

Krazati47 8 55 1 %>200%14 %>200%14 %

Cobenfy60 3 63 73 %>200%81 %>200%81 %

Other Growth Products(a) 244 409 653 (1)%32 %17 %32 %17 %

Total Growth Portfolio 4,974 2,585 7,560 14 %15 %15 %13 %14 %

Legacy Portfolio

Eliquis3,357 1,124 4,481 27 %9 %22 %7 %21 %

Revlimid352 72 425 (52)%(32)%(49)%(30)%(49)%

Pomalyst/Imnovid131 73 204 (78)%(41)%(71)%(38)%(71)%

Sprycel52 35 88 (23)%(32)%(27)%(30)%(26)%

Abraxane12 43 55 (62)%(40)%(47)%(40)%(47)%

Other Legacy Products(b) 112 58 170 12 %(53)%(24)%(53)%(24)%

Total Legacy Portfolio 4,017 1,405 5,422 (4)%(7)%(4)%(7)%(5)%

Other Revenue(c)

— (9)(9)N/AN/AN/AN/AN/A

Total Revenues$8,991 $3,982 $12,973 6 %6 %6 %5 %5 %

**    See "Use of Non-GAAP Financial Information".

(a)    Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.

(b)    Includes other mature brands.

(c)    Includes revenue hedging activities in 2026.

(d)    Worldwide (WW) includes U.S. and International (Int'l).

(e)     For the above table and all subsequent tables, certain totals may not sum due to rounding. Percentages have been calculated using unrounded amounts.

2

SECOND QUARTER COST & EXPENSES

The table below presents selected line-item information.

GAAPNon-GAAP**

Three months ended June 30,Three months ended June 30,

($ amounts in millions) 2026

2025

Change

2026

2025

Change

Cost of products sold $3,726 $3,372 11%$3,711 $3,356 11%

Gross margin 71.3 %72.5 %(120) bps71.4 %72.6 %(120) bps

Selling, general and administrative 1,826 1,713 7%1,826 1,691 8%

Research and development 2,959 2,580 15%2,316 2,263 2%

Acquired IPRD(a) — 1,508 (100)%— 1,508 (100)%

Amortization of acquired intangible assets

437 830 (47)%— — N/A

Other (income)/expense, net

(61)494 NM126 (108)NM

Effective tax rate 18.8 %25.9 %(710) bps16.5 %16.1 %40 bps

** See "Use of Non-GAAP Financial Information" and r